Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Nextpower Inc. Common Stock (NXT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Nextpower Inc. Common Stock — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.72 (market cap $1.66B), while Nextpower Inc. Common Stock trades at $81.37 (market cap $13.47B). The key difference: Nextpower Inc. Common Stock is far larger — about 8.1× Nuvation Bio Inc. Class A Common Stock's market cap, and Nuvation Bio Inc. Class A Common Stock is trading nearer its 52-week high, Nextpower Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 6 Days and Nextpower Inc. Common Stock for 0 Days on average.
| NUVB | NXT | |
|---|---|---|
Market Cap | $1.66B | $13.47B |
Volume | 7,608,075 | 2,009,302 |
Sector | Health | Energy |
52-Week High | $9.54 | $156.40 |
52-Week Low | $3.41 | $77.93 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $1.25B | $12.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvation Bio (NUVB) trades at $4.72, down 3.67% today, with a bearish technical outlook despite strong analyst support. The biopharma company shows promising revenue growth with $170M projected for 2026 but remains unprofitable with negative margins. Recent FDA approval for IBTROZI and Fast Track designation for safusidenib provide clinical catalysts, though cash burn remains elevated with -$121M operating cash flow in 2026.
Wall Street maintains strong bullish sentiment with 80% buy ratings and $20.50 price target (334% upside), but investors face significant execution risk as the company burns cash to commercialize new oncology therapies. The stock offers high-risk, high-reward potential dependent on successful commercialization and path to profitability.
NXT trades at $88.77, up 4.61% today, with strong analyst support (86% buy ratings) and a $144.67 consensus price target suggesting 63% upside. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected November 16. Revenue grew from $3.0B in 2025 to $3.6B in 2026, while maintaining robust profitability with 16.36% net margins and 27.22% ROE.
Positive outlook driven by $5.5B+ backlog and raised 2027 guidance, though rising platform investment costs and solar sector volatility present risks. Technical levels show support at $86 with resistance at $91, while valuation multiples (P/E 22.94, P/S 3.76) appear reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Nextpower Inc. Common Stock
Nextpower Inc., formerly known as Nextracker, is a solar energy technology company that designs tracking systems, structural foundations, and electrical balance-of-system equipment for utility-scale solar power plants. The company also develops software for solar yield management and is expanding into utility-scale power conversion systems.
Read more on NXT →
